Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cor Integrilin Higher Dosing Data First Quarter FDA Filing Expected

Executive Summary

Cor Therapeutics expects to file study data with FDA during the first quarter for a change in the Integrilin (eptifibatide) dosing regimen for patients undergoing coronary stent procedures.

You may also be interested in...



Cor Integrilin

FDA approves supplemental indication for eptifibatide June 8 for patients with acute coronary syndrome, including those undergoing percutaneous coronary intervention. Approval is based on data from Cor's ESPRIT trial (1"The Pink Sheet" Jan. 15, p. 7)

Cor Integrilin

FDA approves supplemental indication for eptifibatide June 8 for patients with acute coronary syndrome, including those undergoing percutaneous coronary intervention. Approval is based on data from Cor's ESPRIT trial (1"The Pink Sheet" Jan. 15, p. 7)

Cor/Schering Integrilin Revenue Recovery Projected After Label Change

Cor Therapeutics expects Integrilin efficacy data and the co-promotional deal with Genentech will help the company recover from the recent inventory drawdown of the peptide glycoprotein IIb/IIIa receptor antagonist.

Related Content

UsernamePublicRestriction

Register

PS037176

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel